CSPC Pharmaceutical Group Ltd (CSPC) is a pharmaceutical company, which provides innovative, generic and bulk drugs. The company manufactures, research and markets medicines and pharmaceutical related products. CSPC product portfolio includes capsules, tablets, injections, caffeine and antibiotics such as acarbose, penicillin sodium, cefazolin sodium and meropenem. The company offers its products for various diseases including ovarian cancer, breast cancer, hypertension and leukemia. Its drugs focus on major therapeutic areas such as neurology, diabetes, cardio-cerebrovascular, oncology and anti-infective. The company operates in the Americas, Europe and Asia. CSPC Pharma is headquartered in Shijiazhuang, Hebei, China.
Headquarters
China
Address
No. 226 Huanghe Avenue, Shijiazhuang, Hebei, 050035
Website
www.cspc.com.hk
Telephone
86 311 87037015
No of Employees
23,500
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1093 (HKG)
Revenue (2022)
$4.4B
1.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-3.6%
(2022 vs 2021)
Market Cap*
$9.0B
Net Profit Margin (2022)
XYZ
-5.1%
(2022 vs 2021)
* As of and is in US$
CSPC Pharmaceutical Group Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Capsules | Distribution of Pharmaceutical Products | Duomeisu |
| Tablets | Research and Development | Oulaining |
| Injections | Enxi | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In March, the company secured clinical trial approval granted from the National Medical Products Administration of the People’s Republic of China to commence clinical trials in China for weight management in overweight adults or obese patients. |
| 2024 | Regulatory Approval | In February, the company received marketing approval for Mingfule (recombinant human TNK tissue-type plasminogen activator for injection) (rhTNK-tPA) (1.0×107 IU/16 mg/injection) by the National Medical Products Administration of the People’s Republic of China. |
| 2023 | Regulatory Approval | In November, the company's SYS-6011 secured approval from China’s National Medical Products Administration to enter clinical trials in China for solid tumors. |
Competitor Comparison
| Key Parameters | CSPC Pharmaceutical Group Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Sino Biopharmaceutical Ltd | Zhejiang Medicine Co Ltd | China Medical System Holdings Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | Hong Kong | China | Hong Kong |
| City | Shijiazhuang | Shanghai | Hong Kong | Shaoxing | Hong Kong |
| State/Province | Hebei | Shanghai | - | Zhejiang | Guangdong |
| No. of Employees | 23,500 | 40,370 | 25,806 | 6,208 | 5,622 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Cai Dongchen | Chairman | Executive Board | - | - |
| Zhang Cuilong | Chief Executive Officer; Vice Chairman | Executive Board | 2022 | - |
| Li Chunlei | Director | Executive Board | 2017 | - |
| Pan Weidong | Director | Executive Board | 2006 | - |
| Wang Qingxi | Director | Executive Board | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward